Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ('Adagene”) (Nasdaq: ADAG) ...
A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact ...
GlobalData on MSN
March Bio’s MB‑105 gains FDA RMAT for CD5+ T‑cell lymphoma
March Biosciences (March Bio) has received US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT ...
This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...
The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to ...
The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...
The transcription factor HEB synergizes with TCR signaling to upregulate Id3, which is required for the maturation of fetal IL-17-producing γδ T cells.
The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.
News Medical on MSN
Development of therapeutic cancer vaccines based on cancer immunity cycle
Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback